Dr. Peter Marks, an esteemed vaccine official at the U.S. Food and Drug Administration (FDA), recently tendered his resignation, citing concerns surrounding the dissemination of misleading information. Marks, who previously served as director of the Center for Biologics Evaluation and Research at the FDA, outlined his decision in a resignation letter dated March 28. In the letter, obtained by KFF reporter Stephanie Armour, Marks pointed to the actions of U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., as a significant factor influencing his choice to step down.
:max_bytes(150000):strip_icc():format(jpeg)/Peter-Marks-032924-9115108c6ac247e7aae2e09f4a4f646c.jpg)
The resignation letter reflected Marks’ belief that the pursuit of truth and transparency was at odds with Secretary Kennedy’s stance, which appeared to favour misinformation and falsehoods. An HHS spokesperson responded to Marks’ departure by emphasizing the importance of upholding scientific integrity and promoting transparency within the FDA. The tense exchange underscores the escalating divisions between health officials and policymakers over matters of public health and vaccine advocacy.
Sources familiar with the situation revealed that Marks faced pressure to leave his position, with reports suggesting that he was given an ultimatum to either resign voluntarily or face termination. Marks, who had been a pivotal figure at the FDA since 2012, played a crucial role in overseeing the evaluation of biological products, including vaccines. His departure marks the latest in a series of high-profile exits from the FDA, raising concerns about the agency’s stability and leadership in the midst of a public health crisis.
Kennedy, a vocal critic of vaccines, assumed the role of HHS Secretary just last month, drawing scrutiny for his controversial statements on vaccination. Despite Marks’ efforts to engage with Kennedy on the issue of vaccine advocacy, tensions between the two escalated, ultimately leading to Marks’ resignation. The clash highlights the ongoing debate surrounding vaccination policies and the dissemination of accurate health information to the public.
Amid a resurgence of measles and tuberculosis outbreaks in Kansas, policymakers are grappling with the decision to relax vaccine requirements, further complicating efforts to contain the spread of infectious diseases. The divergence in opinions between public health officials and policymakers underscores the challenges in navigating the complex intersection of science, public health, and political agendas.
Marks’ departure comes at a critical juncture for the FDA, which has witnessed a significant turnover in leadership in 2025. With multiple top officials, including Dr. Patrizia Cavazzoni and Jim Jones, stepping down earlier in the year, concerns about the agency’s ability to navigate the evolving landscape of public health crises have come to the forefront. The implications of these departures on the FDA’s regulatory oversight and vaccine approval processes remain unclear.
As the public health landscape continues to evolve, the resignation of Dr. Peter Marks underscores the pressing need for collaboration and evidence-based decision-making in addressing complex health challenges. The clash between health officials and policymakers serves as a sobering reminder of the critical importance of upholding scientific integrity and promoting transparent communication in safeguarding public health. Amid escalating tensions and shifting priorities in the realm of vaccination policies, the need for a coherent and evidence-based approach to public health governance has never been more apparent.